Study of bb2121 in Multiple Myeloma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Kristen Hege, MD
Celgene Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford Cancer Center
Stanford, California, United States
- National Cancer Institute
Bethesda, Maryland, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Hackensack University Medical Center
Hackensack, New Jersey, United States
- Mt. Sinai Medical Center Division of Hematology/oncology
New York, New York, United States
- Sarah Cannon Research Inst
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Dec 2015
- Primary completion
- 22 Jul 2019
- Completion
- 22 Sept 2022
- Last update posted
- 23 Jan 2023
- Registered enrollment
- 67
- Registry id
- NCT02658929
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.